Page last updated: 2024-08-05 11:23:23

benzylisoquinoline alkaloid

Any isoquinoline alkaloid based on a benzylisoquinoline skeleton.

ChEBI ID: 22750

Members (7)

MemberDefinitionRole
bicucullineA benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.bicuculline
laudanineA benzyltetrahydroisoquinoline that is norlaudanosoline carrying four methyl substituents at positions N-1, O-6, O-7 and O-4'.laudanine; rac-laudanosoline
noscapineA benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects.(-)-noscapine
papaverineA benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.papaverine
reticulinreticuline
tetrahydropapaverineA benzylisoquinoline alkaloid that is norlaudanosoline in which the four phenolic hydrogens have been replaced by methyl groups.1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
tetrahydropapaverolinenorlaudanosoline

Research

Studies (12,860)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-19905,646 (43.90)18.7374
1990's3,141 (24.42)18.2507
2000's2,444 (19.00)29.6817
2010's1,377 (10.71)24.3611
2020's252 (1.96)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials348 (2.50%)5.53%
Reviews384 (2.76%)6.00%
Case Studies311 (2.23%)4.05%
Observational7 (0.05%)0.25%
Other12,874 (92.46%)84.16%